Phio Pharmaceuticals (NASDAQ:PHIO) issued its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08), Fidelity Earnings reports.
Shares of PHIO traded up $0.01 during trading hours on Tuesday, hitting $0.37. The stock had a trading volume of 75,750 shares, compared to its average volume of 81,825. The company has a debt-to-equity ratio of 0.04, a quick ratio of 8.52 and a current ratio of 8.52. The company has a market capitalization of $9.06 million, a price-to-earnings ratio of -0.35 and a beta of 1.83. The stock has a fifty day simple moving average of $0.39. Phio Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $2.19.
Separately, ValuEngine raised Phio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Featured Story: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.